Mass Spectrometry

Latest News

Alan G. Marshall
A Life Measured in Peaks: Honoring Alan George Marshall (1944–2025)

June 18th 2025

A pioneer of FT-ICR Mass Spectrometry, Alan G. Marshall (1944–2025), is best known for co-inventing Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS), a transformative technique that enabled ultrahigh-resolution analysis of complex mixtures. Over a career spanning more than five decades at institutions like the University of British Columbia, The Ohio State University, and Florida State University, he published over 650 peer-reviewed papers and mentored more than 150 scientists. Marshall’s work profoundly impacted fields ranging from astrobiology to petroleomics and earned him numerous prestigious awards and fellowships. Revered for his intellect, mentorship, and dedication to science, he leaves behind a legacy that continues to shape modern mass spectrometry.

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Future of Laser-Based Technologies in Space Exploration: An Interview with Kelsey Williams, Part IV

May 2nd 2025

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Role of LIBS in ChemCam and SuperCam: An Interview with Kelsey Williams, Part III

May 2nd 2025

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Potential of Mass Spectrometry in Planetary Exploration: An Interview with Kelsey Williams, Part II

May 2nd 2025

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Role of LIBS and Mass Spectrometry in Planetary Exploration: An Interview with Kelsey Williams, Part I

May 2nd 2025

More News


table2-web.jpg

The Role of Liquid Chromatography–Mass Spectrometry in the Characterization of Therapeutic Monoclonal Antibodies

May 1st 2016

Monoclonal antibodies (mAbs) have been increasingly used as biotherapeutic agents and a number of new mAbs are currently in the drug pipeline. Over the next five years the patent on at least nine major biotherapeutic monoclonal antibodies will expire, opening the door for development and marketing of generic forms known as Biosimilars. In this paper a review of the central role mass spectrometry coupled to liquid chromatography plays in characterizing these antibodies is presented. Contemporary top down and middle-up approaches using mass spectrometry and various novel separation techniques to measure the intact masses of mAbs and their subunits or domains are highlighted. Example data of an innovator mAb, Humira (adalimumab) are presented showing the identities and relative abundances of the isoforms associated with this mAb. Similarly the current state of classical peptide mapping using reversed-phase chromatography and tandem mass spectrometry with scan- dependent acquisition is briefly reviewed. Novel approaches that speed analysis and provide information on post translational modifications, glycosylation, and disulfide mapping are discussed. Example data of stressed and unstressed samples of adalimumab are also presented to demonstrate peptide mapping data and modifications to the antibody. Lastly, the current use of mass spectrometry in glycoprofiling of mAbs is reviewed. Example glycan data for adalimumab generated by a novel labeling scheme and sensitive to detection by both fluorescence and mass spectrometry will be presented.